1
|
Hassouna I, Ott C, Wüstefeld L, Offen N, Neher RA, Mitkovski M, Winkler D, Sperling S, Fries L, Goebbels S, Vreja IC, Hagemeyer N, Dittrich M, Rossetti MF, Kröhnert K, Hannke K, Boretius S, Zeug A, Höschen C, Dandekar T, Dere E, Neher E, Rizzoli SO, Nave KA, Sirén AL, Ehrenreich H. Revisiting adult neurogenesis and the role of erythropoietin for neuronal and oligodendroglial differentiation in the hippocampus. Mol Psychiatry 2016; 21:1752-1767. [PMID: 26809838 PMCID: PMC5193535 DOI: 10.1038/mp.2015.212] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Revised: 11/10/2015] [Accepted: 11/13/2015] [Indexed: 12/22/2022]
Abstract
Recombinant human erythropoietin (EPO) improves cognitive performance in neuropsychiatric diseases ranging from schizophrenia and multiple sclerosis to major depression and bipolar disease. This consistent EPO effect on cognition is independent of its role in hematopoiesis. The cellular mechanisms of action in brain, however, have remained unclear. Here we studied healthy young mice and observed that 3-week EPO administration was associated with an increased number of pyramidal neurons and oligodendrocytes in the hippocampus of ~20%. Under constant cognitive challenge, neuron numbers remained elevated until >6 months of age. Surprisingly, this increase occurred in absence of altered cell proliferation or apoptosis. After feeding a 15N-leucine diet, we used nanoscopic secondary ion mass spectrometry, and found that in EPO-treated mice, an equivalent number of neurons was defined by elevated 15N-leucine incorporation. In EPO-treated NG2-Cre-ERT2 mice, we confirmed enhanced differentiation of preexisting oligodendrocyte precursors in the absence of elevated DNA synthesis. A corresponding analysis of the neuronal lineage awaits the identification of suitable neuronal markers. In cultured neurospheres, EPO reduced Sox9 and stimulated miR124, associated with advanced neuronal differentiation. We are discussing a resulting working model in which EPO drives the differentiation of non-dividing precursors in both (NG2+) oligodendroglial and neuronal lineages. As endogenous EPO expression is induced by brain injury, such a mechanism of adult neurogenesis may be relevant for central nervous system regeneration.
Collapse
Affiliation(s)
- I Hassouna
- Clinical Neuroscience, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany,On leave of absence from Physiology
Unit, Zoology Department, Faculty of Science, Menoufia University,
Al Minufya, Egypt
| | - C Ott
- Clinical Neuroscience, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany
| | - L Wüstefeld
- Clinical Neuroscience, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany
| | - N Offen
- Department of Neurosurgery,
University of Würzburg, Würzburg,
Germany
| | - R A Neher
- Evolutionary Dynamics and Biophysics,
Max Planck Institute for Developmental Biology,
Tübingen, Germany
| | - M Mitkovski
- Light Microscopy Facility, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany
| | - D Winkler
- Clinical Neuroscience, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany
| | - S Sperling
- Clinical Neuroscience, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany
| | - L Fries
- Department of Neurosurgery,
University of Würzburg, Würzburg,
Germany
| | - S Goebbels
- Department of Neurogenetics, Max
Planck Institute of Experimental Medicine,
Göttingen, Germany
| | - I C Vreja
- Department of Neuro- and Sensory
Physiology, University Medical Center
Göttingen, Germany,International Max Planck Research
School Molecular Biology, Göttingen,
Germany
| | - N Hagemeyer
- Clinical Neuroscience, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany
| | - M Dittrich
- Department of Bioinformatics,
Biocenter, University of Würzburg, Würzburg,
Germany
| | - M F Rossetti
- Clinical Neuroscience, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany
| | - K Kröhnert
- Department of Neuro- and Sensory
Physiology, University Medical Center
Göttingen, Germany
| | - K Hannke
- Clinical Neuroscience, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany
| | - S Boretius
- Department of Diagnostic Radiology,
Christian-Albrechts-Universität, Kiel,
Germany
| | - A Zeug
- Cellular Neurophysiology, Hannover
Medical School, Hannover, Germany
| | - C Höschen
- Department of Ecology and Ecosystem
Management, Lehrstuhl für Bodenkunde, Technische Universität
München, Freising-Weihenstephan,
Germany
| | - T Dandekar
- Department of Bioinformatics,
Biocenter, University of Würzburg, Würzburg,
Germany
| | - E Dere
- Clinical Neuroscience, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany
| | - E Neher
- Department of Membrane Biophysics,
Max Planck Institute for Biophysical Chemistry,
Göttingen, Germany,DFG Center for Nanoscale Microscopy
and Molecular Physiology of the Brain, Göttingen,
Germany
| | - S O Rizzoli
- Department of Neuro- and Sensory
Physiology, University Medical Center
Göttingen, Germany,DFG Center for Nanoscale Microscopy
and Molecular Physiology of the Brain, Göttingen,
Germany
| | - K-A Nave
- Department of Neurogenetics, Max
Planck Institute of Experimental Medicine,
Göttingen, Germany,DFG Center for Nanoscale Microscopy
and Molecular Physiology of the Brain, Göttingen,
Germany
| | - A-L Sirén
- Department of Neurosurgery,
University of Würzburg, Würzburg,
Germany
| | - H Ehrenreich
- Clinical Neuroscience, Max Planck
Institute of Experimental Medicine, Göttingen,
Germany,DFG Center for Nanoscale Microscopy
and Molecular Physiology of the Brain, Göttingen,
Germany,Clinical Neuroscience, Max Planck Institute of
Experimental Medicine, Hermann-Rein-Str.3,
Göttingen
37075, Germany. E-mail:
| |
Collapse
|
3
|
Abstract
BACKGROUND In 1990, the AIDS Coalition to Unleash Power (ACT-UP) sparked a year long boycott of Philip Morris's Marlboro cigarettes and Miller beer. The boycott protested the company's support of Senator Jesse Helms (R-North Carolina), a leading opponent of AIDS funding and civil rights for lesbian, gay, bisexual and transgender (LGBT) people. ACT-UP demanded that Philip Morris sever its ties with Helms and acknowledge its responsibility to the LGBT community and to people with AIDS. OBJECTIVE To assess the impact of the boycott on the LGBT community, the tobacco industry, and the tobacco control movement; and to determine what lessons tobacco control advocates can extract from this case. DATA SOURCES Internal tobacco industry documents and newspaper archives. METHODS Search of tobacco industry documents websites using "boycott", "ACT-UP", "gay", and other terms. RESULTS Philip Morris used the boycott to its own advantage. It exploited differences within the community and settled the boycott by pledging large donations to combat AIDS. Through corporate philanthropy, Philip Morris gained entrée to the LGBT market without appearing gay friendly. Many LGBT organisations, thirsty for recognition and funding from mainstream corporations, welcomed Philip Morris's overtures without considering the health hazards of tobacco. CONCLUSIONS Unless the goal of a boycott is to convince the tobacco industry to abandon tobacco altogether, such actions invite the industry to expand its marketing under the guise of philanthropy. Tobacco control advocates should be clear about goals and acceptable settlement terms before participating in a boycott of a tobacco company.
Collapse
Affiliation(s)
- N Offen
- University of California, San Francisco, USA.
| | | | | |
Collapse
|